News | April 06, 2026
Red Nucleus acquires Bridge Medical Consulting with advisory support from VERTICES PARTNERS
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
As part of the deal, Red Nucleus also gains indirect ownership of the company’s Indian arm
The JADE trial enrolled 164 U.S. patients who initially received three monthly doses of OLN324 or faricimab, followed by 12 weeks off treatment with retreatment allowed only if disease recurred
Rs 66 lakh acquisition will support DNA engineering and novel cell-gene therapy alternatives to conventional chemotherapy
Key FDA decisions and pivotal late-stage obesity and breast cancer data could reshape competitive positioning
The center brings together hands on technology demonstrations, application expertise, and commercial operations
Broadens downstream purification portfolio with next-generation Protein A chromatography for scalable manufacturing
Kedar Upadhye has also been appointed as Chief Financial Officer of Biocon Limited
Beyond clinical trials, real-world evidence is adding weight to AbbVie’s claims
High-level results from the Phase III OBERON and TITANIA trials revealed that the first-in-class monoclonal antibody reduced the annual rate of moderate-to-severe COPD exacerbations compared with placebo
TERN-701, a next-generation therapy targeting chronic myeloid leukemia (CML), a form of blood cancer that still presents treatment challenges despite decades of advances
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
